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Abstract
Background: Crohn’s disease (CD) has the highest prevalence among individuals of Ashkenazi Jewish (AJ) descent
compared to non-Jewish Caucasian populations (NJ). We evaluated a set of well-established CD-susceptibility
variants to determine if they can explain the increased CD risk in the AJ population.
Methods: We recruited 369 AJ CD patients and 503 AJ controls, genotyped 22 single nucleotide polymorphisms
(SNPs) at or near 10 CD-associated genes, NOD2, IL23R, IRGM, ATG16L1, PTGER4, NKX2-3, IL12B, PTPN2, TNFSF15 and
STAT3, and assessed their association with CD status. We generated genetic scores based on the risk allele count
alone and the risk allele count weighed by the effect size, and evaluated their predictive value.
Results: Three NOD2 SNPs, two IL23R SNPs, and one SNP each at IRGM and PTGER4 were independently associated
with CD risk. Carriage of 7 or more copies of these risk alleles or the weighted genetic risk score of 7 or greater
correctly classified 92% (allelic count score) and 83% (weighted score) of the controls; however, only 29% and 47%
of the cases were identified as having the disease, respectively. This cutoff was associated with a >4-fold increased
disease risk (p < 10e-16).
Conclusions: CD-associated genetic risks were similar to those reported in NJ population and are unlikely to
explain the excess prevalence of the disease in AJ individuals. These results support the existence of novel, yet
unidentified, genetic variants unique to this population. Understanding of ethnic and racial differences in disease
susceptibility may help unravel the pathogenesis of CD leading to new personalized diagnostic and therapeutic
approaches.
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Background
Crohn’s disease (CD) is one of the forms of inflamma-
tory bowel disease (IBD) resulting from defects in the
regulation of mucosal immune responses to enteric bac-
teria in genetically susceptible individuals (reviewed in
[1,2]). Familial aggregation [3,4] and higher concordance
rates in monozygotic than dizygotic twins [5,6] have
provided robust evidence for the involvement of genetic
factors in the disease etiology. Also, an important epide-
miological feature of CD is that it occurs at significantly
different frequencies in different ethnic, demographic
and racial groups [7], and has the highest prevalence
among individuals of Ashkenazi Jewish (AJ) descent
[8,9]. Although the underlying mechanism(s) responsible
for ethnic differences remain unclear, it has been
hypothesized that the substantially increased risk in AJ
versus NJ CD can be explained by the higher frequency
and/or greater magnitude of the effect of susceptibility
gene variants.
The today largest meta-analysis of six genome-wide
association studies (GWAS) have reported 71 confirmed
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pathogenesis is reasonably well defined (reviewed in
[11]).
The strongest and most consistently replicated genetic
CD-risk factors are three variants within the nucleotide-
binding oligomerization domain containing 2 gene
(NOD2,a l s ok n o w na sCARD15), namely, p.G908R,p .
R702W,a n dp . L 1007fs [12-14]. These three variants
have been shown to increase the odds of developing CD
by two- to four-fold [15]. There are additional variants
of the NOD2 gene that also have been implicated to
increase CD risk [16-18]. Another well-validated gene is
the interleukin 23 receptor (IL23R), a regulatory cyto-
kine involved in the initiation of innate and adaptive
immune responses. In the IL23R gene, a rare non-
synonymous variant, p.R381Q, appears to be protective
against developing CD in both AJ and NJ populations
[16]. Also, several common variants at the autophagy-
inducing genes, ATG16L1, autophagy-related 16-like 1,
and IRGM, immunity-related guanosine triphosphatase,
have been reported through GWAS to be associated
with CD in Caucasian populations [17,19-21]. In addi-
tion, a locus on chromosome 5p13.1 in the vicinity of
the prostaglandin E receptor 4 (subtype EP4) gene,
PTGER4,a l s oe m e r g e da sh a v i n gC Ds u s c e p t i b i l i t y
[18,19].
Modest variation in CD risk has been attributed to
additional genes, NKX2-3, a member of the NKX family
of homeodomain-containing transcription factors
involved in the intestinal inflammatory response [19-21];
IL12B, a cytokine which is a member of the IL12/IL23
pathway playing a key role in chronic intestinal inflam-
mation [19,20]; PTPN2, a protein tyrosine phosphatase
that serves as a key negative regulator of inflammatory
responses [19-21]; TNFSF15, a member of the tumor
necrosis factor superfamily previously reported to be
associated with CD in European and Japanese popula-
tions [19,22], and STAT3, a signal transducer and activa-
tor of transcription with a central role in Th17
differentiation and IL10 signaling [19,23].
Despite consistent replication of the association of
these gene variants with CD in various cohorts of Eur-
opean descent, a number of unanswered questions
remain regarding the actual risk associated with carrying
multiple variants, and the degree to which these variants
m a ye x p l a i nt h ee x c e s sr i s ko fC Do b s e r v e di nt h eA J
population. Therefore, this study was designed to deter-
mine allele frequencies and to test the joint contribution
of the 22 independently replicated susceptibility loci to
CD risk in a clinically well-defined AJ population, and
to evaluate if combinations of these alleles could help
predict CD status.
Materials and methods
Study Population
A total of 369 unrelated individuals of AJ descent with
CD were recruited from the New York metropolitan
area and from Israel. All patients were seen by gastroen-
terologists, their diagnoses were based on clinical, endo-
scopic, radiological, and/or histopathological findings
using established criteria [24], and each patient provided
a blood sample. A total of 503 AJ individuals referred
for prenatal carrier testing for Jewish genetic diseases at
the Mount Sinai Medical Center served as controls [25].
No phenotypic information, including the CD status,
was available on controls. Self-reported ethnicity was
assigned on the basis of having four grandparents of AJ
origin in both cases and controls. The study was
approved by the relevant institutional review board(s),
and informed consent was obtained from each
participant.
SNP Selection and Genotyping
We used previous GWAS and candidate gene studies to
select the 22 most replicated CD-related single nucleo-
tide polymorphisms (SNPs) at or near 10 genes (see
Additional file 1, Table S1 online). DNA was extracted
from peripheral blood using the Purgene procedure
(Gentra Systems Inc, Minneapolis, MN). Genotyping
was performed using Taqman assays on an Applied Bio-
systems PRISM 7900HT Sequence Detection System
according to the manufacturer’s protocol (Life Technol-
ogies, Carlsbad, CA). The specific assays used for geno-
typing are listed in Additional file 1, Table S1 online.
Statistical Analysis
Observed genotype frequencies among the AJ controls
were compared with those expected under Hardy-Wein-
berg equilibrium using a c
2 test. Pairwise linkage dise-
quilibrium (LD) was assessed using Lewontin’sD ’ and r
2
as implemented in Haploview [26]. For each variant,
univariate logistic regression was used to calculate allelic
odds ratios (ORs) of CD for risk allele carriers versus
non-carriers. Multivariate logistic regression was applied
to estimate the combined effect of the genetic variants
on the disease status. In addition, to estimate the predic-
tive value of multiple susceptibility loci on disease sta-
tus, we constructed two genetic risk profiles based on
the SNPs that sustained statistical significance in the
multivariate model. First, we assigned each person a
score based on the number of risk alleles carried for the
SNPs significantly associated with CD risk in the multi-
variate model. We assigned “0” to common allele homo-
zygote carriers, “1” for heterozygotes, and “2” for rare
allele homozygotes. Second, we calculated a score that
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SNP by the strength of their association as determined
by regression coefficients [27] based on odds ratios
obtained in the multivariate model. Namely, we multi-
plied ORs by 0, 1, or 2 according to the number of risk
alleles carried by each person.
We evaluated the number of risk alleles and weighted
score as predictors of genetic susceptibility in logistic
regression analyses using different cutoff points. A two-
tailed P < 0.05 was considered statistically significant.
All analyses were performed using SAS/STAT and SAS/
Genetics software version 9.1 (SAS Institute, Inc., Cary,
North Carolina, USA).
Results
The observed genotype frequencies among the controls
did not significantly differ from those expected under
Hardy-Weinberg equilibrium for any of the variants
under study. The risk allele distribution for CD cases
and unaffected controls is shown in Table 1. For the
three extensively studied NOD2 variants, each high risk
allele was associated with a significantly increased risk
of CD, such as 1.9 (95% CI: 1.1-3.2; p = 0.03) for p.
R702W,3 . 2( 9 5 %C I :2 . 2 - 4 . 9 ;p=6 . 4 * 1 0
-9)f o rp . G908R,
and 5.2 (95% CI: 3.3-8.3; p = 2.0*10
-12) for p.L1007fs.I n
univariate analysis, the presence of at least one of the
three high-risk NOD2 alleles conferred a 4.1 risk for
CD, whereas the presence of two variant copies of the
gene, either the same (homozygotes) or different (com-
pound heterozygotes), conferr e da n8 . 7 - f o l dr i s k( T a b l e
1). Overall, the rate of carriage of any of these risk var-
iants was 43% in AJ CD cases and 15% in AJ controls.
Two additional NOD2 risk variants in intron 2,
rs17221417,a n di n t r o n8 ,rs2076756,w e r es t r o n g l y
linked with the coding variants (D’ = 0.99, r
2 =0 . 1 7
between rs17221417 and p.G908R and D’ = 0.97, r
2 =
0.15 between rs2076756 and p.L1007fs,s e eA d d i t i o n a l
file 1, Table S2 online) and individually showed a 2-fold
increased risk of the disease (Table 1).
The rare IL23R p.R381Q variant (rs11209026)w a s
more frequently found among AJ controls than among
AJ patients (7% versus 2%, respectively) indicating a sig-
nificant reduction in CD risk for carriers (OR = 0.3, 95%
CI: 0.2-0.5; p = 4.7*10
-6). Two non-coding IL23R intron
6 variants linked to rs11209026,( rs11805303 with D’ =
1.0, r
2 =0 . 0 3a n drs7517847 with D’ = 0.86, r
2 = 0.08)
Table 1 Univariate Analysis of Susceptibility Loci with Crohn’s Disease Status.
Gene SNP ID Amino acid substitution Allele frequency OR(95% CI)
1 P-value
Controls (n = 503) Cases (n = 369)
NOD2 rs2066844 p.R702W 0.02 0.04 1.85 (1.08-3.18) 0.03
rs2066845 p.G908R 0.04 0.11 3.23 (2.15-4.85) 6.39*10
-9
rs2066847 p.L1007fs
2 0.02 0.11 5.18 (3.26-8.25) 2.03*10
-12
Carriage
3 0.14 0.34 4.13(3.00-5.67) 1.49*10
-19
Compound Hetero/Homozygous
4 0.01 0.09 8.68 (3.61-20.87) 1.10*10
-8
rs17221417 intron 2 0.22 0.38 2.13 (1.73-2.63) 1.32*10
-12
rs2076756 intron 8 0.22 0.39 2.26 (1.83-2.79) 6.50*10
-14
IL23R rs11209026 R381Q 0.07 0.02 0.27 (0.16-0.48) 4.73*10
-6
rs7517847 intron 6 0.38 0.25 0.55 (0.43-0.68) 6.88*10
-8
rs11805303 intron 6 0.35 0.41 1.32 (1.09-1.61) 0.0076
IRGM rs13361189 intergenic 0.16 0.21 1.47 (1.15-1.88) 0.0014
rs11747270 intergenic 0.15 0.21 1.48 (1.16-1.90) 0.0012
rs1000113 intergenic 0.15 0.21 1.49 (1.17-1.91) 0.0011
PTGER4 rs1373692 p.T300A 0.61 0.67 1.29 (1.06-1.58) 0.012
rs1992660 intergenic, near 5’-UTR 0.60 0.65 1.21 (0.99-1.47) 0.062
rs4613763 intergenic 0.07 0.08 1.05 (0.74-1.51) 0.77
ATG16L1 rs2241880 intergenic 0.59 0.63 1.18 (0.97-1.43) 0.10
rs10210302 intergenic 0.59 0.62 1.14 (0.94-1.39) 0.19
NKX2-3 rs11190140 intergenic, near 5’-UTR 0.45 0.43 0.92 (0.76-1.11) 0.36
IL12B rs6887695 intergenic 0.32 0.32 1.03 (0.84-1.26) 0.81
rs10045431 intergenic 0.71 0.69 0.94 (0.77-1.16) 0.59
PTPN2 rs2542151 intergenic 0.10 0.12 1.20 (0.89-1.63) 0.22
TNFSF15 rs4263839 intron 1 0.76 0.75 0.95 (0.77-1.19) 0.67
STAT3 rs744166 intron 1 0.61 0.62 0.99 (0.82-1.21) 0.93
OR (95% CI), Odds ratio (95% confidence interval);
1 Test for allelic trend;
2 fs, Frame shift;
3 Carriage of at least one of the above three NOD2/CARD15 risk alleles,
and
4 Homozygous carriage of at least one of the above risk alleles or heterozygous carriage of more than one of the above risk alleles.
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the rs7517847 variant possessing a protective effect and
rs11805303 increasing the risk, similar in direction to
their effects in NJ CD [16,17] (Table 1).
In addition, a significant association was detected
between the IRGM minor alleles at rs13361189,
rs11747270,a n drs1000113 and CD risk. All of these
SNPs have similar allele frequencies, were in strong LD
(pairwaise D’>0.99 and r
2>0.95) and associated with a
1.5-fold (95% CI: 1.5-1.9; p = 0.001) increased preva-
lence of CD. Also, carriers of the common tightly linked
variants at PTGER4 rs1373692 and rs1992660 (D’ =
0.96, r
2 = 0.87) had higher odds of developing the dis-
ease than non-carriers. A trend toward a higher fre-
quency of the ATG16L1 rs2241880 and rs10210302
polymorphisms (in LD, D’ = 0.99, r
2 =0 . 9 6 )w a s
observed in CD cases compared to controls, but this
association did not reach statistical significance. No
other variants were detected to be individually asso-
ciated with CD risk in our AJ cohort.
I nam u l t i v a r i a t el o g i s t i cr e g r e s s i o nm o d e l ,o n l yt h r e e
uncommon coding SNPs at NOD2 and one SNP each at
IRGM and PTGER4 were independently associated with
the increased risk of CD, whereas two SNPs at IL23R
showed a protective effect against CD (Table 2). Compar-
ison of the distribution of the total number of these seven
loci in cases and controls showed that individuals with
CD tended to carry more copies of these susceptibility
alleles than unaffected controls (Figure 1). Also, more
CD patients than controls had a higher weighted risk
score (Figure 2). Using these risk scores to distinguish
cases from controls, specificity was high for carriers of ≥7
copies of the seven significant risk alleles and a weighted
score of ≥7 (92.2% and 82.5%, respectively) when the
highest test accuracy was achieved (65.5% and 67.5%,
respectively), implying a relatively low rate of misclassifi-
cation in the absence of the disease. However, this was at
the expense of low sensitivity showing that only 29% and
47% of cases were correctly identified based on the allelic
count and weighted genetic risk scores, respectively
(Table 3). The area under the receiver operating
characteristics (ROC) curve for the two risk models were
70% and 71%, respectively (Figure 3).
The CD risks in the participants with ≥7 copies of the
risk alleles or a weighted score of ≥7 compared to those
with <7 copies of the risk alleles or a weighted score of
<7 were 4.9-fold (95% CI: 3.3-7.2) and 4.2-fold (95% CI:
3.1-5.7), respectively (Table 3).
Discussion
This study was designed to assess the contribution of
established risk variants in selected CD-associated genes
to CD risk in the AJ population, a group known to have
an unusually high prevalence of the disease compared to
NJ European or North American Caucasians. We con-
firmed previous reports of significant association
between variants in several immunity-related genes and
disease susceptibility in Caucasian populations, but they
do not appear to account for the increased CD risk in
the AJ population. NOD2,t h ef i r s tg e n ea s s o c i a t e dw i t h
CD, is a polymorphic gene involved in innate immune
responses. To date, over 60 NOD2 variations have been
identified, several of which are specific to AJ individuals
Table 2 Genetic effects from multivariate regression model.
Gene SNP 1 Copy of risk allele 2 Copies of risk allele Log additive model
Case/Control OR (95% CI) P Case/Control OR (95% CI) P OR (95% CI) P
NOD2 rs2066844 28/20 2.18 (1.17-4.07) 0.015 2/2 2.03 (0.27-15.12) 0.49 2.01 (1.18-3.44) 0.010
rs2066845 67/36 3.05 (1.93-4.80) 1.14*10
-6 6/0 ND - 3.30 (2.16-5.06) 3.92*10
-8
rs2066847 61/22 5.03 (2.93-8.64) 2.99*10
-9 11/1 36.84 (4.55-298.29) 0.0007 5.24 (3.26-8.44) 9.18*10
-12
IL23R rs11209026 15/59 0.44 (0.23-0.84) 0.013 0/6 ND - 0.43 (0.23-0.80) 0.0075
rs7517847 144/210 0.74 (0.54-1.01) 0.06 20/84 0.24 (0.13-0.44) 6.47*10
-8 0.59 (0.47-0.74) 9.20*10
-6
IRGM rs13361189 132/139 1.70 (1.24-2.35) 0.0012 13/9 2.35 (0.93-5.93) 0.072 1.64 (1.24-2.17) 0.0005
PTGER4 rs1373692 160/238 1.18 (0.73-1.90) 0.50 167/188 1.75 (1.09-2.83) 0.021 1.37 (1.10-1.70) 0.0052
OR (95% CI), Odds ratio (95% confidence interval); ND, not determined.
Figure 1 Percentage of participants in each allele count score
category among those who developed CD and those who
remained CD-free based on 7 SNPs at NOD2, IL23R, IRGM, and
PTGER4.
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Page 4 of 9[28,29], with p.R702W,p G908R,a n dp . L1007fs account-
ing for 81% of the genetic variation [30]. These three
variants were present in 43% of our CD patients com-
pared to 15% of controls. Rare variants identified by
sequencing of the NOD2 promoter and exonic regions
in AJ families revealed no association with disease risk
[28]. In the present study, carriage of any one of the
three NOD2 variants was found to be associated with an
over 4-fold increased risk of CD, while carriage of at
least two of the SNPs increased the odds of AJ CD
almost nine times. This is comparable with the esti-
mates of 2.39 (95% CI: 2.00-2.90) and 17.1 (95% CI:
10.7-27.2)-fold increased risk, respectively, reported in a
large meta-analysis of 42 studies conducted predomi-
nantly in NJ populations [15]. Compared to a sub-analy-
sis of six studies that analyzed a total of 1,658
individuals of AJ descent, each variant allele in our
study conferred a slightly higher risk for p.R702W,p .
G908R and p.L1007fs (OR of 1.85 (95% CI: 1.08-3.18),
3.23 (95% CI: 2.15-4.85) and 5.18 (95% CI: 3.26-8.25)
versus 1.74 (95% CI: 0.88-3.42), 1.93 (95% CI: 1.25-3.00),
and 2.45 (95% CI: 1.51-3.98), respectively). While addi-
tional more common non-coding NOD2 variants were
individually associated with CD status in univariate
Figure 2 Percentage of participants in each weighted genetic
risk score category among those who developed CD and those
who remained CD-free based on 7 SNPs at NOD2, IL23R, IRGM,
and PTGER4.
Table 3 Genetic risk profile using CARD15/NOD2, IL23R, PTGER4, and IRGM susceptibility alleles.
Risk profile N (%) OR (95% CI) P Sensitivity Specificity PPV NPV Accuracy
CD Control
Number of risk alleles
≥3 366 (99) 489 (97) 3.49 (0.99-12.24) 0.05 99.2 2.8 42.8 82.4 43.6
≥4 354 (96) 425 (84) 4.33 (2.48-7.66) 5.80*10
-8 95.9 15.5 45.4 83.9 49.5
≥5 316 (86) 310 (62) 3.71 (2.64-5.23) 3.95*10
-15 85.6 38.4 50.5 78.5 58.4
≥6 214 (58) 152 (30) 3.19 (2.41-4.22) 1.94*10
-16 57.9 69.8 58.5 69.4 64.5
≥7 107 (29) 39 (8) 4.86 (3.27-7.22) 9.88*10
-17 29.0 92.2 73.3 63.9 65.5
≥8 27 (7) 3 (0.6) 13.16 (3.96-43.72) 4.29*10
-8 7.3 99.4 90.0 59.4 60.4
Weighted Score
≥2 368 (>99) 498 (99) 3.69 (0.43-31.75) 0.25 99.7 1.0 42.5 83.3 42.8
≥3 361 (99) 470 (93) 3.17 (1.45-6.94) 0.003 97.8 6.6 43.4 80.5 45.2
≥4 331 (90) 377 (75) 2.91 (1.97-4.31) 4.13*10
-8 89.7 25.0 46.8 76.8 52.4
≥5 287 (78) 259 (51) 3.30 (2.44-4.46) 2.42*10
-15 77.8 48.5 52.6 74.8 60.9
≥6 216 (59) 138 (27) 3.73 (2.81-4.97) 1.97*10
-20 58.5 72.6 61.0 70.5 66.6
≥7 174 (47) 88 (17) 4.21 (3.09-5.72) 3.65*10
-21 47.2 82.5 66.4 68.0 67.5
≥8 124 (34) 42 (8) 5.56 (3.79-8.15) 5.14*10
-21 33.6 91.7 74.7 65.3 67.1
≥9 108 (29) 27 (5) 7.69 (4.89-12.11) 3.49*10
-23 29.3 94.6 80.0 64.6 67.0
≥10 73 (20) 20 (4) 9.45 (5.15-17.34) 5.74*10
-18 19.8 96.0 78.5 62.0 63.8
≥11 53 (14) 13 (3) 14.2 (6.04-33.40) 1.76*10
-15 14.4 97.4 80.3 60.8 62.3
OR (95% CI), Odds ratio (95% confidence interval); PPV, Positive predictive value; NPV, Negative predictive value.
Figure 3 Receiver operating curve (ROC) for allele count and
weighted genetic risk scores based on 7 SNPs at NOD2, IL23R,
IRGM, and PTGER4. Diagonal line indicates prediction by chance
alone.
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of the three established NOD2 risk loci.
Since the original report showing a protective effect
on susceptibility to CD of the IL23R non-synonymous
coding variant rs11209026 (p.R381Q)[ 1 6 ] ,n u m e r o u s
reports including GWAS, have underscored the impor-
tance of this allele in lowering IBD risk [18,31,32]. In
our study, the magnitude of protection from CD asso-
ciated with the minor allele at IL23R rs11209026 (p.
R381Q) was comparable to that reported previously in
AJ and NJ cohorts (OR range 0.26-0.41) [16,33] with
one exception, in which rs11209026 was not associated
with protection from CD in an AJ population in Canada
[34]. Notably, we observed higher frequencies of the
rs11209026 variant in AJ controls compared to NJ con-
trols suggesting a greater protection in the AJ popula-
tion. In the present study, two additional non-coding
IL23R variants (rs7517847 and rs11805303) were inde-
pendently associated with CD risk with rs7517847 main-
taining its significance in a multivariate model after the
adjustment for other susceptibility loci. This marker has
been previously implicated in AJ and NJ CD [16,17]. Of
note, the largest today GWAS meta-analysis of ulcera-
tive colitis (UC), another form of IBD, has shown that,
among the 99 confirmed IBD loci meeting genome-wide
significance (P <5×1 0
-8)i nU Ca n d / o rC D ,2 8l o c i
shared association signals between UC and CD, with
many common variants identified in the IL23 signaling
pathway, specifically IL23R, JAK2, STAT3, IL12B,a n d
PTPN2 [35]. The significance of these findings is under-
lined by the central role that IL23 plays in the induction
of IL-17 by Th17 lymphocytes [36].
In addition to confirming several associations between
genetic variants and CD risk, our study, for the first time,
replicated IRGM and PTGER4 as CD susceptibility loci in
the AJ population. Among several IRGM variants indivi-
dually associated with CD risk in univariate analyses, only
intergenic variant rs13361189 survived the adjustment for
other genetic risk factors. That is, in a multivariate
model, we detected a 1.64-fold increased CD risk per
each copy of the IRGM rs13361189 risk allele. An earlier
meta-analysis combining the effects of IRGM rs13361189
across studies of European populations reported a pooled
OR of 1.34 per copy of the variant [37]. Detection of this
polymorphism in the flanking region of the gene
prompted sequencing of the entire gene; however, no
non-synonymous variants associated with the disease
were identified suggesting that the causal variant is unli-
kely to change the amino acid sequence of the IRGM
protein [21]. Moreover, a 20-kb deletion polymorphism,
upstream of IRGM and in perfect linkage disequilibrium
with rs13361189, has been reported to have distinct
expression patterns modulating the cellular autophagy
process in response to intracellular bacteria [38].
Several GWAS have identified a 250-kb region of
chromosome 5p13.1 containing multiple SNPs with
strongly suggestive evidence of disease association
[10,18-21,39]. Despite the fact that this locus is con-
tained within a 1.25-Mb gene desert, there is consistent
evidence that disease-associated alleles correlate with
PTGER4 expression levels. A common intergenic variant
near PTGER4, rs1373692, has been associated with a
1.59-fold increase in CD risk in a Caucasian population
[18]. Our results show that the PTGER4 rs1373692 risk
allele frequency was higher in AJ cases than in AJ con-
trols, translating to a 1.37-fold increase in odds of devel-
oping the disease per one copy of the risk allele. While
the exact mechanism of the PTGER4 variation on the
pathophysiology of CD remains unclear, it is likely that
variants in this locus may modulate PTGER4 expression
levels [18].
Importantly, while similar effect sizes were determined
for the PTGER4 and IRGM risk alleles in the AJ cohort
as in NJs, considerable differences in frequencies were
observed between AJ controls and those reported in the
literature for NJ controls. For the variants that remained
significant in the multivariate model, IRGM rs13361189
was as twice as common in AJ controls than in NJs
(16% versus 8%). Further studies are warranted to
understand the cause and consequences of population
differences in risk allele distribution.
Although we found a trend toward a slightly higher
frequency of the ATG16L1 rs2241880 G allele among AJ
CD cases in univariate analyses, this association did not
reach statistical significance. A previous study found no
association between this variant and the risk of CD in
an AJ population [34]. However, a series of recent meta-
analyses have concluded that this variant is associated
with increased risk of CD in NJ Caucasian populations
[37,40,41]. The meta-analysis of 17 studies that included
over 30,000 subjects showed a significant association
between the ATG16L1 rs2241880 polymorphism and
CD risk with an OR of 1.39 (95% CI: 1.27-1.51) and
1.87 (95% CI: 1.69-2.05) for heterozygote and homozy-
gote risk allele carriers, respectively, compared to wild-
type homozygotes [40]. Two additional meta-analyses
have also shown a strong association between CD and
ATG16L1 rs2241880, finding a 1.62 (95% CI: 1.37-1.91)
and 1.28 (95% CI: 1.06-1.54)-fold increase in CD risk for
single allele carriers [37,41]. Based on our sample size,
we had 80% statistical power to detect an OR of 1.32 or
higher, assuming a log-additive genetic model. Yet, we
cannot rule out a smaller effect of the ATG16L1
rs2241880 variant or involvement of additional SNPs
that might confer a stronger effect in individuals of AJ
descent.
We evaluated the ability to predict CD risk using the
combined information from the seven variants of the
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cant in the multivariate model. The genetic risk profile
was based on the number of multiple risk alleles car-
ried by each individual and their weighed effects. The
highest test prediction accuracy was achieved with the
cut-off of equal to or greater than seven for both allelic
count score and the weighted genetic risk score. While
the specificity of the tests was reasonably high, with
83-92% of controls predicted to not have CD, only
about 29%-47% of the cases were identified as having
the disease.
Genetic risk scores have previously been applied by
other investigators [27,42-44]. A combination of NOD2,
IBD5, NOD1,a n dTNFSF15 genotype and smoking sta-
tus demonstrated comparable sensitivities and specifici-
ties in an earlier study of NJ Caucasian CD cases [27].
Another report claimed to successfully predict a CD
genetic risk profile similar to our study using 10 alleles
at five genes including NOD2, ATG16L1, IRGM, IL23R
and 5p13 (corresponding to the PTGER4 region) in a
European NJ population [44]. Even though these studies
used different combinations of susceptibility loci in their
predictive models, the tradeoff between the sensitivity
and specificity was similar. Further work will be needed
before predictive models can be translated into direct
clinical utility and help clinicians rule out CD in indivi-
duals with symptoms of IBD leading to more efficient
patient management and resource utilization.
Limitations of our study include the fact that our con-
trols were individuals referred for unrelated genetic test-
ing and provided no information on their CD status and
other phenotypic characteristics. Given the low disease
prevalence, it is highly unlikely that more than two or
three affected individuals would be found in the control
group. Nonetheless, even if such misclassification did
occur, this would bias our results toward null. In addi-
tion, AJ ethnicity was self-reported and not verified
using ancestry informative markers. However, a recent
study has shown that within self-described Americans of
European descent, there is a clear genetic corollary
which would permit near perfect inference of AJ ances-
try [45]. Moreover, a relatively small sample size may
have prevented us from detecting modest effects, such
as for the NKX2-3, IL12B, PTPN2, TNFSF15,o rSTAT3
polymorphisms (OR < 1.3; see Additional file 1, Table
S1 online) that were confirmed by the recent and largest
CD meta-analysis [10]. However, even though we cannot
rule out smaller effects of these variants in individuals of
AJ descent, it is unlikely that they are responsible for
excess disease prevalence in this population.
Also, differences in linkage disequilibrium patterns
between AJ and NJ populations may result in the contri-
bution of different genetic markers in the region to dis-
ease susceptibility in individuals of AJ descent. In
addition, due to a limited number of studies that
reported effect sizes of selective CD-related risk variants
in cohorts of AJ descent, we were restricted to using the
same dataset to develop and validate the predictive
models. For the weighted risk score estimation, we used
odds ratios derived using an additive genetic model.
This means that the logarithm of the odds ratio was
assumed to relate linearly to the number of copies of
the higher-risk allele [46]. Thus, the odds ratio reported
was that associated with one copy of the higher-risk
allele, which likely underestimated the effect of risk of
homozygous carriage. This was due to the fact that an
accurate estimation of the genotype-based odds ratios
was not possible for some of the susceptibility loci.
Further studies are warranted to evaluate the perfor-
mance of our models in independent AJ populations.
Conclusions
In summary, the present studies determined for the first
time the magnitude of individual and combined risks of
multiple CD susceptibility loci in the AJ population. We
confirmed previously reported associations of the
NOD2, IL23R, IRGM and PTGER polymorphisms with
CD risk. Genetic effects estimated in the present study
were similar to those observed in other Caucasian popu-
lations and are, thus, unlikely to explain the excessive
prevalence of CD in individuals of AJ descent. Existence
of other, yet unidentified, AJ-specific genetic risk factors
and environmental triggers remain to be determined.
Understanding of population-specific differences in dis-
ease susceptibility may help unravel the pathogenesis of
CD leading to new personalized diagnostic and thera-
peutic approaches.
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